Lixte Biotechnology, a cancer drug discovery company, has received a notice of allowance from the USPTO for its histone deacetylase inhibitor (HDACi), LB-201, and other structural homologs.
Lixte founder and president John Kovach said although there are HDACi approved for certain types of skin lymphomas and other HDACi in various stages of development, the compounds have characteristics which may be advantageous for clinical use.
"As Lixte is predominantly focused on cancer treatment, it is seeking to license the non-neoplastic activities of its proprietary HDACi," Kovach added.
"We believe this inhibitor of serine/threonine phosphatase has the potential to be first-in-class and to have wide applicability for the treatment of diverse cancers."
